AstraZeneca (LON:AZN) Price Target Raised to £178

AstraZeneca (LON:AZN) had its price target increased by Citigroup from £175 to £178 in a research report sent to investors on Tuesday morning,Digital Look reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a research report on Friday, June 26th. Jefferies Financial Group reissued a “buy” rating and issued a £180 target price on shares of AstraZeneca in a research note on Friday, June 26th. Finally, Berenberg Bank restated a “buy” rating and set a £160 target price on shares of AstraZeneca in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of £153.

AstraZeneca Price Performance

AZN opened at £127.20 on Tuesday. AstraZeneca has a one year low of £107.84 and a one year high of £157.32. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. The company’s 50 day simple moving average is £134.30 and its 200-day simple moving average is £140.33. The stock has a market capitalization of £197.27 billion, a P/E ratio of 19.16, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.